Diazoxide choline CR is under clinical development by Soleno Therapeutics and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Diazoxide choline CR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diazoxide choline CR overview

Diazoxide choline controlled release (DCCR) is under development for the treatment of Prader-Willi syndrome, hypothalamic and SH2B1 deficiency obesity, hyperphagic obesity and Smith-Magenis syndrome. The drug candidate is formulated as a tablet and administered through oral route. It targets ATP sensitive inward rectifier potassium channel 11. It is a new chemical entity (NCE). The drug candidate was also under development for the treatment of hypertriglyceridemia and dyslipidemia.

Soleno Therapeutics overview

Soleno Therapeutics (Soleno) formerly Capnia Inc, is a medical equipment company that designs, develops and commercializes novel therapeutic and diagnostic products. The company provides products such as serenz, cosense, and others. It offers serenz that is a hand-held device, which is used to obtain relief from the symptoms of allergies. Soleno provides cosense which is a portable device that is used to measure carbon monoxide in exhaled breath. The company offers various solutions to properly diagnose, monitor and care for children. It markets its products through its network of distributors. Soleno is headquartered in Redwood, California, the US.

For a complete picture of Diazoxide choline CR’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.